These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 24261031)
41. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Jones JL; Loftus EV Inflamm Bowel Dis; 2007 Oct; 13(10):1299-307. PubMed ID: 17600819 [TBL] [Abstract][Full Text] [Related]
42. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Martínez F; Nos P; Pastor M; Garrigues V; Ponce J Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359 [TBL] [Abstract][Full Text] [Related]
43. Myelotoxicity and hepatotoxicity during azathioprine therapy. de Boer NK; Mulder CJ; van Bodegraven AA Neth J Med; 2005 Dec; 63(11):444-6. PubMed ID: 16397313 [TBL] [Abstract][Full Text] [Related]
44. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565 [TBL] [Abstract][Full Text] [Related]
45. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
46. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Korelitz BI; Reddy B; Bratcher J Expert Opin Drug Saf; 2010 May; 9(3):379-82. PubMed ID: 20367524 [TBL] [Abstract][Full Text] [Related]
47. Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. Adler M; Delhaye M; Deprez C; Hardy N; Gelin M; De Pauw L; Vereerstraeten P; Cremer M; Toussaint C Nephrol Dial Transplant; 1987; 2(3):183-8. PubMed ID: 3114679 [TBL] [Abstract][Full Text] [Related]
48. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Russmann S; Zimmermann A; Krähenbühl S; Kern B; Reichen J Eur J Gastroenterol Hepatol; 2001 Mar; 13(3):287-90. PubMed ID: 11293451 [TBL] [Abstract][Full Text] [Related]
49. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235 [TBL] [Abstract][Full Text] [Related]
50. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Fraser AG; Orchard TR; Robinson EM; Jewell DP Aliment Pharmacol Ther; 2002 Jul; 16(7):1225-32. PubMed ID: 12144571 [TBL] [Abstract][Full Text] [Related]
51. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease. van Asseldonk DP; Jharap B; Verheij J; den Hartog G; Westerveld DB; Becx MC; Russel MG; Engels LG; de Jong DJ; Witte BI; Mulder CJ; van Nieuwkerk CM; Bloemena E; de Boer NK; van Bodegraven AA Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972 [TBL] [Abstract][Full Text] [Related]
52. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study. Al Rifai A; Prasad N; Shuttleworth E; McBurney H; Pushpakom S; Robinson A; Newman W; Campbell S Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):153-8. PubMed ID: 21164349 [TBL] [Abstract][Full Text] [Related]
53. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486 [No Abstract] [Full Text] [Related]
54. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. Wahed M; Louis-Auguste JR; Baxter LM; Limdi JK; McCartney SA; Lindsay JO; Bloom SL Aliment Pharmacol Ther; 2009 Sep; 30(6):614-20. PubMed ID: 19552632 [TBL] [Abstract][Full Text] [Related]
55. Idiopathic portal hypertension in a renal transplant patient after long-term azathioprine therapy. Lorenz R; Brauer M; Classen M; Tornieporth N; Becker K Clin Investig; 1992 Feb; 70(2):152-5. PubMed ID: 1600341 [TBL] [Abstract][Full Text] [Related]
56. Current use of immunosuppressive agents in inflammatory bowel disease patients in East China. Huang LJ; Zhu Q; Lei M; Cao Q World J Gastroenterol; 2009 Jun; 15(24):3055-9. PubMed ID: 19554661 [TBL] [Abstract][Full Text] [Related]
57. Azathioprine in inflammatory bowel disease, a safe alternative? Tanis AA Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598 [TBL] [Abstract][Full Text] [Related]
58. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142 [TBL] [Abstract][Full Text] [Related]
59. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Buster EH; van Vuuren HJ; Zondervan PE; Metselaar HJ; Tilanus HW; de Man RA Eur J Gastroenterol Hepatol; 2008 Jan; 20(1):68-72. PubMed ID: 18090994 [TBL] [Abstract][Full Text] [Related]
60. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. Min MX; Weinberg DI; McCabe RP J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]